Slide 1: Welcome Investors
Welcome Investors March 2026
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or th
Slide 3: Who We Are
Who We Are Key Stats: Headquarters: Ticker: Established: Newburyport, MA UFPT 1963 UFP Technologies is a trusted contract development and manufacturing organization specializing in innovative solutions Annual Revenue: Market Cap: 26 of top 30 for medical devices, sterile $603 million – 92% ~$1.7 Bil
Slide 4: Shaping Innovation
Design & engineering capabilities Materials expertise Shaping Innovation We help our customers get their medical devices to market by Precision manufacturing offering expertise in design, materials, and global manufacturing locations Strategic locations Confidential, property of UFP Technologies, In
Slide 5: Our Process
Our Process Innovative process from design and engineering to manufacturing and delivery Confidential, property of UFP Technologies, Inc. 5
Slide 6: Product Development Business
Product Development Business High Margin Added Expertise 1 2 We bring deep experience in flexible material-based device manufacturing, from components and packaging, to BENEFITS final device assembly 3 4 Long Term Stronger Customer Relationships Manufacturing Confidential, property of UFP Technologi
Slide 7: MedTech Portfolio
MedTech Portfolio Robotic Drapes Revascularization Needleless Injection Device Port Cleaner MedSurg Bed Negative Pressure Patient Safety Wound Therapy Confidential, property of UFP Technologies, Inc. 7
Slide 8: MedTech
MedTech MedTech Revenue by Segment3 $550 billion, 6.0% CAGR1 Global Medical Device Market Customers include 26 of the top 30 largest medical device manufacturers in the world2 Global Medical Device CDMO Market4: $101B | ~10% CAGR Devices UFP is uniquely focused on three 55% medical device growth are
Slide 9: Medical Segment Overview: $550 Billion Global Device Market
Medical Segment Overview $550 Billion Global Device Market, 6.0% CAGR1 Therapeutic Area % of Medical Market Sales2 Growth Robotic Surgery 29% Mid Teens Surfaces & Support 23% LDD Interventional & Surgical 21% LSD Infection Prevention 9% MSD Orthopedics 6% MSD Therapeutics 4% MSD Wound Care 4% MSD Di
Slide 10: Surrounding a High-Growth End Market: Robotic Surgery
Surrounding a High-Growth End Market: Robotic Surgery ROBOTIC SURGERY BY THE NUMBERS Acquisition strategy centered upon UFPT is the leading provider of several adding core capabilities to our • Market Size: ~$11B (2024) → ~$23.7B (2029)1 materials / capabilities that are critical for robotic surgery
Slide 11: Growth Strategy
Growth Strategy TWO-PRONGED Internal Growth: Strategic Acquisitions Market To Our Sweet Spot Confidential, property of UFP Technologies, Inc. 11
Slide 12: Organic Growth Opportunity
Market to our sweet spot and differentiated capabilities » Leverage technology differentiation » Engineering resources » Exclusive access to specialty materials » Scale (footprint, clean room manufacturing) Organic Expand business with existing customers Growth » Offer complementary products and ser
Slide 13: Acquisition Growth Opportunity
Continue to Focus on Higher-Growth, Higher-Margin MedTech Opportunities that Create Value » Become more valuable to our customers » Strategic focus – new capability, geography, growing market segment, materials Acquisition » Add scale Growth » Look for synergistic opportunities » Cultural fit Opport
Slide 14: Proven Acquisition Integration Model
Customer Centric MedTech M&A – Growing Segments, Proven Acquisition Integration Model Differentiated Tech MedTech Sales Over Time $555 million 700,000,000 MedTech $451 million 600,000,000 MedTech 500,000,000 400,000,000 $132 million 300,000,000 MedTech 200,000,000 100,000,000 0 2021 2022 2023 2024 2
Slide 15: Locations
Locations New Locations: + Rockville, MD + Añasco, PR 40 1.4 Million Cleanrooms & CERs SF Manufacturing Space Confidential, property of UFP Technologies, Inc. 15
Slide 16: Why Invest?
Why Invest? Significant Barriers Strong Experienced Proven Attractive market to entry customer management growth financial growth relationships team strategy metrics opportunities Confidential, property of UFP Technologies, Inc. 16
Slide 17: Significant Market Growth Opportunities
Focused on fast growing segments Significant Market Growth Market Focused On » Better Patient Outcomes Opportunities » Infection Prevention » Reducing Healthcare Costs Global Footprint » Bringing New Opportunities Confidential, property of UFP Technologies, Inc. 17
Slide 18: Competitive Advantage
Competitive Advantage Greater Access to Engineering Resources Custom Equipment Materials » Veteran engineering team for » Exclusive access to several specialty » In-house custom equipment product design and development; medical grade materials manufacturing capabilities more than 100 members of the
Slide 19: Proven Growth Strategy
Proven Growth Creating Shareholder Value Strategy 19
Slide 20: Financial Targets
Financial Targets Confidential, property of UFP Technologies, Inc. 20
Slide 21: Financial Targets
Financial Targets 3 to 5 Year Financial Targets 12-18% 28-31% 17-20% Revenue Growth Gross Margin Adjusted Operating Margin Confidential, property of UFP Technologies, Inc. 21
Slide 22: Revenue
Revenue $700 $600 $500 $400 12% to 18% $300 fffdkjfk Targeted Revenue Growth $200 Internal Growth + Acquisitions $100 $0 2020 2021 2022 2023 2024 2025 Confidential, property of UFP Technologies, Inc. 22
Slide 23: Gross Profit Margin
Gross Profit 32.0% Margin 30.0% Target: 28-31% 29.1% 28.1% 28.3% 28.0% 26.0% 25.5% 24.9% 24.8% Gross Margin 24.0% Target – 28% to 31% 22.0% Operating Leverage from Mix Shift + Acquisition 20.0% synergies + Efficiencies 18.0% 2020 2021 2022 2023 2024 2025 Confidential, property of UFP Technologies, I
Slide 24: Adjusted Operating Margin
Adjusted* Operating 20.0% Target: 17-20% 18.3% Margin 16.4% 17.1% 15.0% 13.8% 11.1% 10.3% 10.0% Adjusted Operating Margin Target - 17% to 20% 5.0% Operating leverage from mix shift + acquisition synergies + efficiencies 0.0% 2020 2021 2022 2023 2024 2025 *See non-GAAP reconciliation on slide 32 Conf
Slide 25: UFP Historical Stock Performance
15000% 14000% 13000% 12000% 11000% 10000% 9,340% 9000% 8000% 7000% 6000% 5000% UFP Historical 4000% 3000% Stock 2000% 1000% Performance 0% 441% 268% 20 Years UFP Technologies (UFPT) Price % Change Russell 2000 (RUT) Price % Change S&P 500 (SPX) Price % Change *Measured as the percent increase from F
Slide 26: Jeff Bailly CEO, Ron Lataille CFO
Jeff Bailly CEO Newburyport, Massachusetts Ron Lataille CFO, Sr. VP & Treasurer Newburyport, Massachusetts UFP Technologies Newburyport, MA 01950 www.ufpt.com 100 Hale St. 978-352-2200 investorinfo@ufpt.com Confidential, property of UFP Technologies, Inc.
Slide 27: Appendix: Reconciliation of Non-GAAP Results
Appendix Reconciliation of Non-GAAP Results (in Millions) 2020 2021 2022 2023 2024 2025 Revenue, As Reported $ 179.4 $ 206.3 $ 353.8 $ 400.1 $ 504.4 $ 602.8 Operating Income, as Reported 16.7 21.2 55.4 57.7 80.9 92.3 Add: Purchase Accounting Expenses - - - - 1.1 0.2 Add: Acquisition Related Costs -